慢性肾臟病药物市场：按药物类别、给药途径、患者类型、分销渠道、地区 - 规模、份额、前景和机会分析，2022-2030 年

慢性肾病是一种肾功能在多年内逐渐衰退的疾病。慢性肾臟病也称为慢性肾病。随着肾臟疾病的恶化，大量废物积聚在血液中。与慢性肾病相关的其他问题包括高血压、红细胞计数低、骨骼脆弱、营养不良和神经病。

引起慢性肾病的主要原因包括糖尿病、高血压、慢性肾小球肾炎、慢性肾盂肾炎、长期服用抗炎药、自身免疫性疾病、多囊肾、阿尔波特病、先天性畸形、肾病急性期延长等。

市场动态

市场上的主要参与者正专注于获得监管批准，预计这将在预测期内推动市场增长。例如，2020 年 9 月，专注于开发一流药物以改善肾臟和心血管疾病患者治疗的生物製药公司 Arderix 宣布，接受透析治疗的慢性肾病 (CKD) 成人患者宣布美国食品药品监督管理局 (U.S. Food)和药物管理局 (FDA) 已接受替那帕醇用于控制血清磷的新药申请 (NDA)

政府机构为提高认识所做的努力、慢性肾病患病率的增加以及产品的推出正在推动全球慢性肾病药物市场的增长。例如，美国疾病控制与预防中心在 2021 年发表的一篇文章估计，超过七分之一的人，即 15% 的美国成年人，即 3700 万人患有慢性肾病。根据同一消息来源，与 18-44 岁的人群相比，慢性肾病在 45-64 岁的人群 (12%) 和 65 岁以上的人群 (38%) 中更为常见。

这项研究的主要特点

• 本报告对全球慢性肾臟病药物市场进行了深入分析，显示了以 2021 年为基准年的预测期（2022-2030 年）的市场规模和復合年增长率 (CAGR%)。I在这里。
• 解释了不同细分市场的潜在创收机会，并描述了针对该市场的有吸引力的投资建议矩阵。
• 我们还提供有关市场驱动因素、制约因素、机会、新产品发布或批准、市场趋势、区域前景以及主要参与者采用的竞争战略的重要见解。
• 根据公司亮点、产品组合、主要亮点、绩效和策略等参数介绍全球慢性肾病治疗市场主要参与者的概况。
• 本研究涵盖的主要公司包括赛诺菲、阿斯利康公司、安进公司、再生元製药公司、艾伯维公司、ProKidney 公司、辉瑞公司、拜耳公司、F. Hoffmann-La Roche AG、Kissei Pharmaceutical Co., Ltd.、Reata Pharmaceuticals, Inc.、GlaxoSmithKline plc.、Ardelyx, Inc.、Boehringer Ingelheim International GmbH、Novo Nordisk A/S、Novartis AG、Johnson & Johnson、Astellas Pharma Inc.、Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc. , Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals 和 KBP Biosciences Co. ., 有限公司
• 这份报告中的见解将使营销人员和企业高管能够就未来的产品发布、类型升级、市场扩张和营销策略做出明智的决策。我猜。
• 本报告面向该行业的各种利益相关者，包括投资者、供应商、产品製造商、分销商、新进入者和金融分析师。
• 利益相关者可以通过用于分析全球慢性肾病治疗市场的各种战略矩阵来促进决策制定。

内容

第 1 章目的和先决条件

• 调查目的
• 先决条件
• 缩写说明

第二章市场展望

• 报告内容
  • 市场定义和范围
• 执行摘要
  • 市场概况：按药物类别
  • 按给药途径划分的市场概况
  • 市场概况：按患者类型分类
  • 市场概况：按分销渠道
  • 市场概况：按地区
• 连贯机会图 (COM)

第 3 章市场动态、法规和趋势分析

• 市场动态
  • 司机
  • 约束因素
  • 市场机会
• 监管情景
• 主要亮点
• 研究与开发
• 联合研究、併购方案
• 主要发展
• 最近的产品批准和发布
• 害虫分析
• 管道分析
• 流行病学

第 4 章全球慢性肾臟病药物市场-冠状病毒 (COVID-19) 大流行的影响

• COVID-19 对市场的影响
• 对全球慢性肾病药物市场的影响
• 对临床试验的影响

第 5 章。全球慢性肾臟病药物市场：按药物类别分类，2017-2030

• ACE 抑製剂
• 血管紧张素受体阻滞剂 (ARB)
• B 受体阻滞剂
• 钙拮抗剂
• 袢利尿剂
• 红细胞生成促进剂 (ESA)
• 磷酸盐结合剂
• 其他

第 6 章。全球慢性肾臟病药物市场：按给药途径，2017-2030

• 口服给药
• 皮下给药
• 静脉给药

第 7 章。全球慢性肾病药物市场：按患者类型分列，2017-2030

• 人工透析
• 其他

第 8 章。全球慢性肾臟病药物市场：分销渠道，2017-2030

• 医院药房
• 零售药房
• 在线药店

第 9 章。全球慢性肾臟病药物市场：地区，2017-2030

• 北美
• 美国
• 加拿大
• 拉丁美洲
• 巴西
• 墨西哥
• 阿根廷
• 其他拉丁美洲地区
• 欧洲
• 英国
• 德国
• 意大利
• 法国
• 西班牙
• 俄罗斯
• 其他欧洲地区
• 亚太地区
• 中国
• 印度
• 日本
• 东盟
• 澳大利亚
• 韩国
• 其他亚太地区
• 中东
• 海湾合作委员会
• 以色列
• 其他中东地区
• 非洲
• 北非
• 中非
• 南非

第10章竞争格局

• 热图分析
• 公司简介
  • Sanofi
  • AstraZeneca plc.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • ProKidney Corp.
  • Pfizer, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Kissei Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Kibow Biotech, Inc.
  • FibroGen, Inc.
  • Cara Therapeutics
  • Pieris Pharmaceuticals, Inc.
  • Mitsubishi Chemical Group Corporation
  • Pharmacosmos A/S
  • OPKO Health, Inc.
  • Covis Pharma
  • Tricida, Inc.
  • Eli Lilly and Company
  • Biosidus S.A.
  • Teva Pharmaceutical Industries Ltd.
  • YUHAN
  • Caladrius Biosciences, Inc.
  • UnicoCell Biomed CO. LTD.
  • Akebia Therapeutics, Inc.
  • Caladrius Biosciences, Inc.
  • Allena Pharmaceuticals
  • KBP Biosciences Co., Ltd.

第 11 章章节

• 参考资料
• 调查方法

Chronic kidney disease is a condition which is characterized by gradual loss of kidney function over time. Chronic kidney disease is also known as chronic renal disease. The kidney disease gets worse, wastes can build to high levels in your blood; other problems associated to chronic kidney disease are high blood pressure, a low red blood cell count, weak bones, poor nutrition, and nerve damage.

The main causes of chronic kidney disease include diabetes, hypertension, chronic glomerulonephritis, chronic pyelonephritis, chronic use of anti-inflammatory medication, autoimmune diseases, polycystic kidney disease, Alport disease, congenital malformations, and prolonged acute renal disease.

Market Dynamics

Key players in market are focused on gaining approvals from regulatory bodies, which is expected to drive the market growth over the forecast period. For instance, in September 2020, Ardelyx, Inc., a biopharmaceutical company focused on developing first-in-class medicines to improve treatment for people with kidney and cardiovascular diseases, announced that the U.S. Food and Drug Administration (FDA) has accepted its New Drug Application (NDA) of tenapanor for the control of serum phosphorus in adult patients with chronic kidney disease (CKD) on dialysis.

Factors such as awareness initiatives by government bodies, increasing prevalence of chronic kidney disease, and product launches are driving the global chronic kidney disease drugs market growth. For instance, according to an article published by Centers for Disease Control and Prevention in 2021, more than 1 in 7, that is 15% of the U.S. adults or 37 million people, are estimated to have chronic kidney disease. According to same source, chronic kidney disease is more common in people aged 65 years or older (38%) than in people aged 45-64 years (12%) or 18-44 years.

Key features of the study:

• This report provides an in-depth analysis of the global chronic kidney disease drugs market, and provides market size (US$ Million) and compound annual growth rate (CAGR%) for the forecast period (2022-2030), considering 2021 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global chronic kidney disease drugs market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
• Key companies covered as a part of this study include Sanofi, AstraZeneca plc., Amgen, Inc., Regeneron Pharmaceuticals, Inc., AbbVie Inc., ProKidney Corp., Pfizer, Inc., Bayer AG, F. Hoffmann-La Roche AG, Kissei Pharmaceutical Co., Ltd., Reata Pharmaceuticals, Inc., GlaxoSmithKline plc., Ardelyx, Inc., Boehringer Ingelheim International GmbH, Novo Nordisk A/S, Novartis AG, Johnson & Johnson, Astellas Pharma Inc., Takeda Pharmaceutical Company Limited, Jiangsu Hansoh Pharmaceutical Group Co., Ltd., Kibow Biotech, Inc., FibroGen, Inc., Cara Therapeutics, Pieris Pharmaceuticals, Inc., Mitsubishi Chemical Group Corporation, Pharmacosmos A/S., OPKO Health, Inc., Covis Pharma, Tricida, Inc., Eli Lilly and Company, Biosidus S.A., Teva Pharmaceutical Industries Ltd., YUHAN, Caladrius Biosciences, Inc., UnicoCell Biomed CO. LTD, Akebia Therapeutics, Inc., Allena Pharmaceuticals, and KBP Biosciences Co., Ltd.
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global chronic kidney disease drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global chronic kidney disease drugs market.

Detailed Segmentation:

• Global Chronic Kidney Disease Drugs Market, By Drug Class:
  • ACE Inhibitors
  • Angiotensin Receptor Blockers (ARBs)
  • B-Blockers
  • Calcium Channel Blockers
  • Loop Diuretics
  • Erythropoiesis-Stimulating Agents (ESAs)
  • Phosphate Binders
  • Others
• Global Chronic Kidney Disease Drugs Market, By Route of Administration:
  • Oral
  • Subcutaneous
  • Intravenous
• Global Chronic Kidney Disease Drugs Market, By Patient Type:
  • Dialysis
  • Others
• Global Chronic Kidney Disease Drugs Market, By Distribution Channel:
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
• Global Chronic Kidney Disease Drugs Market, By Region:
  • North America
    • By Country
  • U.S.
  • Canada
  • Latin America
    • By Country
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • By Country
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • By Country
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • ASEAN
  • Rest of Asia Pacific
  • Middle East
    • By Country
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • By Region/Country
  • South Africa
  • Central Africa
  • North Africa
• Company Profiles
  • Sanofi*
    • Company Highlights
    • Products Portfolio
    • Key Highlights
    • Financial Performance
    • Strategies
  • AstraZeneca plc.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • ProKidney Corp.
  • Pfizer, Inc.
  • Bayer AG
  • Hoffmann-La Roche AG
  • Kissei Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc.
  • GlaxoSmithKline plc
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Kibow Biotech, Inc.
  • FibroGen, Inc.
  • Cara Therapeutics
  • Pieris Pharmaceuticals, Inc.
  • Mitsubishi Chemical Group Corporation
  • Pharmacosmos A/S
  • OPKO Health, Inc.
  • Covis Pharma
  • Tricida, Inc.
  • Eli Lilly and Company
  • Biosidus S.A.
  • Teva Pharmaceutical Industries Ltd.
  • YUHAN
  • Caladrius Biosciences, Inc.
  • UnicoCell Biomed CO. LTD
  • Akebia Therapeutics, Inc.
  • Allena Pharmaceuticals
  • KBP Biosciences Co., Ltd.

"*" marked represents similar segmentation in other categories in the respective section.

Table of Contents

1. Research Objectives and Assumptions

• Research Objectives
• Assumptions
• Abbreviations

2. Market Purview

• Report Description
  • Market Definition and Scope
• Executive Summary
  • Market Snapshot, By Drug Class
  • Market Snapshot, By Route Of Administration
  • Market Snapshot, By Patient Type
  • Market Snapshot, By Distribution Channel
  • Market Snapshot, By Region
• Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

• Market Dynamics
  • Drivers
  • Restraints
  • Market Opportunities
• Regulatory Scenario
• Key Highlights
• Research and Development
• Collaboration, Mergers, and Acquisitions Scenario
• Key Development
• Recent Product Approvals and Launches
• PEST Analysis
• Pipeline Analysis
• Epidemiology

4. Global Chronic Kidney Disease Drugs Market- Impact of Coronavirus (Covid-19) Pandemic

• COVID-19 Impact on the market
• Impact on Global Chronic Kidney Disease Drugs Market
• Impact on Clinical Trials

5. Global Chronic Kidney Disease Drugs Market, By Drug Class, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• ACE Inhibitors
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Angiotensin Receptor Blockers (ARBs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• B-Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Calcium Channel Blockers
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Loop Diuretics
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Erythropoiesis-Stimulating Agents (ESAs)
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Phosphate Binders
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

6. Global Chronic Kidney Disease Drugs Market, By Route Of Administration, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Oral
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Subcutaneous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Intravenous
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

7. Global Chronic Kidney Disease Drugs Market, By Patient Type, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Dialysis
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Others
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

8. Global Chronic Kidney Disease Drugs Market, By Distribution Channel, 2017 - 2030, (US$ Million)

• Overview
  • Market Share Analysis, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, 2017 - 2030
  • Segment Trends
• Hospital Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Retail Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)
• Online Pharmacies
  • Overview
  • Market Size and Forecast, and Y-o-Y Growth, 2017-2030, (US$ Million)

9. Global Chronic Kidney Disease Drugs Market, By Region, 2017 - 2030, (US$ Million)

• Introduction
  • Market Share Analysis, By Region, 2022 and 2030 (%)
  • Y-o-Y Growth Analysis, For Regions, 2017-2030
  • Regional Trends
• North America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.S.
• Canada
• Latin America
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• Brazil
• Mexico
• Argentina
• Rest of Latin America
• Europe
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• U.K.
• Germany
• Italy
• France
• Spain
• Russia
• Rest of Europe
• Asia Pacific
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• China
• India
• Japan
• ASEAN
• Australia
• South Korea
• Rest of Asia Pacific
• Middle East
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• GCC
• Israel
• Rest of Middle East
• Africa
  • Introduction
  • Market Size and Forecast, and Y-o-Y Growth, By Drug Class, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Patient Type 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2017 - 2030, (US$ Million)
  • Market Size and Forecast, and Y-o-Y Growth, By Country, 2017 - 2030, (US$ Million)
• North Africa
• Central Africa
• South Africa

10. Competitive Landscape

• Heat Map Analysis
• Company Profiles
  • Sanofi
• Company Highlights
• Product Portfolio
• Key Highlights
• Financial Performance
• Market Strategies
  • AstraZeneca plc.
  • Amgen, Inc.
  • Regeneron Pharmaceuticals, Inc.
  • AbbVie Inc.
  • ProKidney Corp.
  • Pfizer, Inc.
  • Bayer AG
  • F. Hoffmann-La Roche AG
  • Kissei Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals, Inc.
  • GlaxoSmithKline plc.
  • Ardelyx, Inc.
  • Boehringer Ingelheim International GmbH
  • Novo Nordisk A/S
  • Novartis AG
  • Johnson & Johnson
  • Astellas Pharma Inc.
  • Takeda Pharmaceutical Company Limited
  • Jiangsu Hansoh Pharmaceutical Group Co., Ltd.
  • Kibow Biotech, Inc.
  • FibroGen, Inc.
  • Cara Therapeutics
  • Pieris Pharmaceuticals, Inc.
  • Mitsubishi Chemical Group Corporation
  • Pharmacosmos A/S
  • OPKO Health, Inc.
  • Covis Pharma
  • Tricida, Inc.
  • Eli Lilly and Company
  • Biosidus S.A.
  • Teva Pharmaceutical Industries Ltd.
  • YUHAN
  • Caladrius Biosciences, Inc.
  • UnicoCell Biomed CO. LTD.
  • Akebia Therapeutics, Inc.
  • Caladrius Biosciences, Inc.
  • Allena Pharmaceuticals
  • KBP Biosciences Co., Ltd.

11. Section

• References
• Research Methodology
• About Us and Sales Contact